RBC Capital Maintains Outperform on Nuvation Bio, Raises Price Target to $5
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Kennen MacKay has maintained an Outperform rating on Nuvation Bio (NUVB) and increased the price target from $4 to $5.
April 17, 2024 | 2:56 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RBC Capital has maintained an Outperform rating on Nuvation Bio and raised the price target from $4 to $5.
The upgrade in price target by a reputable analyst like Kennen MacKay from RBC Capital suggests a positive outlook on Nuvation Bio's stock. Such endorsements often lead to increased investor confidence and can drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100